Europe In Vivo Cro Market Size & Outlook, 2023-2030

The in vivo cro market in Europe is expected to reach a projected revenue of US$ 2,737.2 million by 2030. A compound annual growth rate of 7.8% is expected of Europe in vivo cro market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,615.9
Forecast, 2030 (US$M)
$2,737.2
CAGR, 2024 - 2030
7.8%
Report Coverage
Europe

Europe in vivo cro market highlights

  • The Europe in vivo cro market generated a revenue of USD 1,615.9 million in 2023.
  • The market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
  • In terms of segment, small molecule was the largest revenue generating modality type in 2023.
  • Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
  • Country-wise, Spain is expected to register the highest CAGR from 2024 to 2030.


Europe data book summary

Market revenue in 2023USD 1,615.9 million
Market revenue in 2030USD 2,737.2 million
Growth rate7.8% (CAGR from 2023 to 2030)
Largest segmentSmall molecule
Fastest growing segmentLarge Molecule
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSmall Molecule, Large Molecule
Key market players worldwideIQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group


Other key industry trends

  • In terms of revenue, Europe region accounted for 35.0% of the global in vivo cro market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 823.6 million by 2030.

Small molecule was the largest segment with a revenue share of 63.61% in 2023. Horizon Databook has segmented the Europe in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.


In 2022, Europe accounted for the second-largest market share. Growth in the region can be attributed to the increase in big pharmaceutical outsourcing expenditure, focus on rare diseases with unmet needs, patent expiry of biologicals, and the arrival of new biosimilars. In Europe, the field of drug discovery is undergoing rapid transformation.

Advancements in combinatorial chemistry, genomics, high throughput screening, and proteomics have revolutionized the process of moving drugs from the discovery phase to the development phase. This is primarily due to the substantial increase in available data, facilitated by the advancements in database management systems.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

In Vivo CRO Market Companies

Name Profile # Employees HQ Website

Europe in vivo cro market size, by country, 2018-2030 (US$M)

Europe In Vivo CRO Market Outlook Share, 2023 & 2030 (US$M)

Europe in vivo cro market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more